CD274 and esophageal squamous cell carcinoma: In this meta-analysis, findings showed that patients with ESCC and low or negative PD-L1 expression who are treated with anti–PD-1–based regimens may not be conferred a survival advantage, consistent with the EMA approval of nivolumab plus chemotherapy for patients with ESCC and a TPS of 1% or higher.